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1In this issue of Circulation: Cardiovascular Interventions, a Polish institution carefully analyzed ≈100 patients undergo-
ing left atrial appendage (LAA) occlusion with serial trans-
esophageal echocardiographies or computer tomographies at 
1.5 (early), 3 to 6 (late), and 12 (very late) months with partic-
ular focus on device-related thrombus (DRT) and peridevice 
leak (PDL).1 The patients were treated without oral antico-
agulation but with dual antiplatelet therapy for 1 to 6 months 
at the discretion of the operators. DRT was diagnosed in 7%. 
The distribution of DRTs to the 3 control intervals was quite 
even: 2% early, 2% late, and 3% very late. Of these 7 DRTs, 4 
resolved by adding low–molecular weight heparin to the anti-
platelet treatment and 3 persisted in spite of treatment adjust-
ment. One of the patients with DRT had a stroke which was 
fatal. None of the patients without DRT had an embolic event 
during the 1-year follow-up.
See Article by Pracon et al
The 2 most common devices, the Amplatzer and the 
Watchman occluders, were used for about half of the cases 
each. Deep implantation was found to be the most significant 
predictor for DRT. The distance of the most proximal part of the 
device to the tip of the pulmonary ridge, the structure separat-
ing the LAA from the left upper pulmonary vein, was used for 
the definition of deep implantation. For the Amplatzer device, 
a 2-component structure consisting of an anchoring lobe and a 
covering disc according to the pacifier principle2 any position 
not covering the peak of the pulmonary ridge was considered 
deep intubation. This resulted in 3 out of 4 Amplatzer patients 
meeting that definition. For the Watchman device, consisting 
of a single jellyfish-like plug, the definition was more lenient 
and only 1 out of 3 patients met it. Deep implantation has been 
identified as a problem for DRT with the Amplatzer device 
before, but a definition was used that makes more sense.3,4 The 
venous ridge encompasses only a small part of the circumfer-
ence of the os of the LAA. Hence, opposing the Amplatzer disc 
to it may lift the disc off the wall of the left atrium where the 
venous ridge rises. This engenders leaks underneath the disk. 
The importance of them is unknown.
The importance of PDL, defined as flow past the lobe of 
the Amplatzer device or the Watchman device into the fundus 
of the LAA, was scrutinized for a relationship with dual anti-
platelet therapy by the authors. They found none. This confirms 
earlier studies.5–9 It had even been suggested that repositioning a 
device to decrease the risk of PDL may not be justified because 
this maneuver may increase the risk for pericardial bleeding.7
An important lesson of the article is that not only 
Amplatzer devices but also Watchman devices can be used 
safely with a post-treatment of only antiplatelet agents. This 
has been the rule for Amplatzer devices from the start.10–12 
For the Watchman device, 6 weeks of oral anticoagulation 
is still standard, although literature on a simplified treatment 
with antiplatelet only is accruing.13,14 It might be questioned 
whether the 3 doses of low–molecular weight heparin given to 
the patients described in this study immediately after implan-
tation laid a more favorable ground for thrombus-free further 
evolution compared with a therapy completely based on anti-
platelets as it is usually adopted after Amplatzer implantation. 
Reports using no heparin or oral anticoagulation after implan-
tation and even stopping platelet inhibitors completely after a 
few months in patients with no other indications for it showed 
during follow-up either more or less than the 7% DRTs 
observed in this study. They used exclusively transesophageal 
echocardiography for follow-up examination and the defini-
tion of thrombus varied. It was 4%8 to 5%3 in studies with 
Amplatzer devices using varying treatment regimens. Other 
reports used more sensitive definitions of DRT and came up 
with 16%11 or even 18%.15 Notwithstanding, worrisome DRT 
is most certainly going to happen but in a single digit per-
centage, irrespective of the anticoagulation treatment applied. 
Clinical events associated with DRT found on routine exami-
nations are invariably low (≤1%). So, not only PDLs but also 
most DRTs represent more a cosmetic than a clinical problem.
Nonetheless, we must have a common language defining 
PDL and DRT. The Amplatzer device has 2 kinds of leaks, 
a leak just reaching the space between lobe and disc and a 
leak reaching the fundus of the LAA. The Watchman device 
can only have the latter. The pacifier principle with Amplatzer 
devices is meant to decrease PDLs and has been shown to be 
effective in that respect if only leaks are counted that reach the 
fundus of the LAA. Such PDL rates were 5% for Amplatzer 
devices and 15% for Watchman devices in this study.1 Again, 
there is probably no clinical meaning to that.
There must be a clinical meaning to undulating DRTs 
although that has not been specifically examined to date. The 
Figure depicts various types of DRTs and points out the ones 
that represent a clinical hazard and should entrain reinforced 
anticoagulation, if at all possible.
The informative article shows that the 2 market leader 
devices for LAA occlusion have a similarly low potential for 
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clinically relevant DRT. It showed a 3× larger but still clini-
cally insignificant risk for PDL in the case of the Watchman 
device. DRTs can usually be treated safely with a simple anti-
platelet regimen which usually consists of dual antiplatelet 
therapy for at least 1 month (a single antiplatelet agent may 
suffice, but this was never examined). This is important as the 
most common indication for LAA occlusion is poor or no tol-
erance for oral anticoagulation and every day the patient can 
spend without oral anticoagulation is a blessing.
Major banes of LAA occlusion remain the relative intri-
cacy of implantation with a shallow learning curve and the 
risk of acute complications such as pericardial bleeding and 
device embolization. Periprocedural ischemic events can 
almost completely be avoided with proper technique and pre-
implantation imaging excluding mobile thrombi on the way. 
Follow-up clinical problems are fortunately extremely rare, 
and this constitutes the major advantage of LAA occlusion 
over continued oral anticoagulation with unrelenting and even 
increasing risk for bleeding over time.
Transesophageal echocardiography or computer tomogra-
phy imaging on the lookout of silent DRT may be justified at 
least once but only the dangerous types (Figure) should be 
reacted to. PDL does not need to be looked for or if found 
to be reacted on. Exceptions are those already appearing as 
uncovered lobes at the end of the implantation procedure.
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Figure. Classification of different types of thrombus on left atrial appendage (LAA) occluders. A1: Normal endocardialization of an 
Amplatzer occluder; A2: undulating thrombus attached to the central screw of an Amplatzer occluder; A3: tissue filling of a dead space 
between the disc of an Amplatzer occluder and the left atrium (LA); A4: tissue filling and undulating thrombus on an Amplatzer occluder; 
W1: normal endocardialization of a Watchman occluder; W2: tissue filling of the dead space between the device and the LA of a some-
what more deeply implanted Watchman occluder; and W3: tissue filling and on undulating thrombus on a Watchman occluder. Only the 
situations in A2, A4, and W3 require further or intensified anticoagulation as they seem to represent a clinical hazard. MV indicates mitral 
valve; and PR, pulmonary ridge.
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